Evidence mapPaperPMID 35796695Full record

Trial reportJournal of medicinal food2022

Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial.

Thais Borges Cesar, Fernanda Maria Manzini Ramos, Carolina Barbosa Ribeiro

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of medicinal food, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06005142 (Therapeutic Intervention of Nutraceutical Eriomin Associated with Metformin to Improve the Control of Hyperglycemia in Patients with Prediabetes), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06005142 naactive not recruitingnot on this mapstarted 2024, after this paper: background citation

Therapeutic Intervention of Nutraceutical Eriomin Associated with Metformin to Improve the Control of Hyperglycemia in Patients with Prediabetes: a Double-blind, Randomized, Placebo-controlled Crossover Clinical Trial

TypeinterventionalSponsorThais CesarRan2024 to 2024Enrolled80ConditionsPre-diabetesArmsEriomin, Washout, Placebo
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Thais Borges CesarLaboratory of Nutrition, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara, São Paulo, Brazil.ORCID 0000-0001-7878-7075
Fernanda Maria Manzini RamosLaboratory of Nutrition, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara, São Paulo, Brazil.
Carolina Barbosa RibeiroLaboratory of Nutrition, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara, São Paulo, Brazil.
Centro Universitário de Araraquara · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This double-blind, randomized, placebo/controlled, crossover study evaluated the efficacy of Eriomin

Indexed as

Diabetes MellitusDiabetes Mellitus, Type 2HyperglycemiaBlood GlucoseCross-Over StudiesDietary SupplementsDouble-Blind MethodFlavanonesGlucagon-Like Peptide 1HumansHypoglycemic AgentsInflammationInsulinBlood GlucoseeriocitrinFlavanonesGlucagon-Like Peptide 1Hypoglycemic AgentsInsulincitrus flavonoidseriocitrinGLP-1hyperglycemianutraceuticalsystemic inflammation

Identifiers

PMID35796695
PMCPMC9700344
OpenAlexW4284890880

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.